Company intelligence / Profile preview
Aleta Biotherapeutics
Natick, Massachusetts, United Statesaletabio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Aleta’s lead asset ALETA‑001 is in a Phase 1/2 trial for patients relapsed/refractory to CD19-targeting CAR T therapy. The company’s CTEs are designed to enhance the efficacy of existing CAR T therapies by increasing target antigen density and overcoming resistance. Early clinical data and preclinical results suggest potential to improve response rates in high unmet need populations such as relapsed B-cell malignancies and multiple myeloma. Clinical trials began in February 2024 and are ongoing; no published efficacy results yet.
- Therapeutic areas
- Oncology
- Modalities
- Biologics (CAR T Engagers/CTEs)Cell therapies (CAR T-cell therapy)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Cancer Research UK Centre for Drug Development – major collaborator/funder on ALETA–001 clinical trials
Beyond the preview
Go deeper on Aleta Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aleta Biotherapeutics.